8
ALL8
JemincareYear
8
ALL1
20241
20233
20223
2021DEALS // DEV.
8
ALL4
Deals4
DevelopmentsCountry
8
ALL8
CHINA8
ALL1
Genentech4
Inapplicable2
Orion Corporation1
Rapt TherapeuticsTherapeutic Area
8
ALL4
Infections and Infectious Diseases2
Neurology1
Oncology1
Pulmonary/Respiratory DiseasesStudy Phase
8
ALL1
Phase II3
Phase I4
IND EnablingDeal Type
8
ALL2
Agreement4
Inapplicable2
Licensing AgreementProduct Type
8
ALL3
Antibody1
Other Large Molecule4
Other Small MoleculeDosage Form
8
ALL3
Intravenous Infusion2
Oral3
UndisclosedLead Product
8
ALL3
JMB20022
JMKX0006231
JMKX0029921
JMKX0038011
JYB1904Target
8
ALL1
Androgen receptor2
NaV1.8 Sodium Channel3
SARS-CoV-2-viral spike protein2
UndisclosedLead Product(s) : JYB1904
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Rapt Therapeutics
Deal Size : $707.5 million
Deal Type : Licensing Agreement
RAPT, Jemincare License Novel Anti-IgE Antibody With Long-Acting Therapeutic Effects
Details :
Product Name : RPT904
Product Type : Other Large Molecule
Upfront Cash : $35.0 million
December 23, 2024
Lead Product(s) : JYB1904
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Rapt Therapeutics
Deal Size : $707.5 million
Deal Type : Licensing Agreement
Lead Product(s) : JMKX003801
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs
Details :
Product Name : JMKX003801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 26, 2023
Lead Product(s) : JMKX003801
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JMKX002992
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Genentech
Deal Size : $650.0 million
Deal Type : Licensing Agreement
Details :
Product Name : JMKX002992
Product Type : Other Small Molecule
Upfront Cash : $60.0 million
August 18, 2022
Lead Product(s) : JMKX002992
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Genentech
Deal Size : $650.0 million
Deal Type : Licensing Agreement
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : JMKX000623
Product Type : Other Small Molecule
Upfront Cash : $15.8 million
June 05, 2022
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : JMKX000623
Product Type : Other Small Molecule
Upfront Cash : $16.1 million
June 05, 2022
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : JMB2002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : JMB2002
Product Type : Antibody
Upfront Cash : Inapplicable
September 13, 2021
Lead Product(s) : JMB2002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JMB2002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
Details :
Product Name : JMB2002
Product Type : Antibody
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : JMB2002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JMB2002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jemincare Initiates Phase I Clinical Trial of anti-SARS-CoV-2 Neutralizing Antibody JMB2002
Details :
Product Name : JMB2002
Product Type : Antibody
Upfront Cash : Inapplicable
January 20, 2021
Lead Product(s) : JMB2002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable